{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:24:41Z","timestamp":1773239081820,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Colchicine prophylaxis to prevent gout flares when commencing urate\u2010lowering therapy is recommended by international rheumatology society guidelines. Whether this is a cost\u2010effective intervention is currently unknown. Our objective was to perform a cost\u2010effectiveness analysis using both a US cost input model and an Australian cost input model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This cost\u2010effectiveness analysis was completed from the point of view of the third\u2010party payer. We used a 2\u2010arm decision tree with 1 arm commencing allopurinol with no colchicine prophylaxis and the other with colchicine prophylaxis. Model inputs were drawn from published literature where available. We completed a univariate and probabilistic sensitivity analysis to confirm the robust nature of the modeling. The time frame for the model was 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The colchicine prophylaxis arm resulted in a cost of $1,276 and 0.49 quality\u2010adjusted life\u2010years (QALYs), while in the placebo arm the cost was $516 and 0.47 QALYs, with an incremental cost\u2010effectiveness ratio of $34,004 per QALY gained. In Australia, where cost of colchicine was much lower, the colchicine arm dominated the placebo ($208 [Australian] in the colchicine arm versus $415 [Australian] in the placebo). Univariate and probability sensitivity analysis demonstrated that results were robust to changes in input parameters. In the probabilistic sensitivity analysis, the probability of colchicine prophylaxis being the most cost\u2010effective option was 93% in the US and 100% in the Australian setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Colchicine prophylaxis to prevent gout flares while commencing allopurinol in gout is very cost\u2010effective.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.24357","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T13:27:50Z","timestamp":1592400470000},"page":"1537-1543","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cost\u2010Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol"],"prefix":"10.1002","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-3418","authenticated-orcid":false,"given":"Philip C.","family":"Robinson","sequence":"first","affiliation":[{"name":"Royal Brisbane and Women\u2019s Hospital and University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-4476","authenticated-orcid":false,"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[{"name":"University of Auckland  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Donovan","sequence":"additional","affiliation":[{"name":"Royal Brisbane and Women\u2019s Hospital and University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40807"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150310"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_2_6_5_1","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad GC","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.01.008"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21773"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex156"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23672"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-015-3285-7"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1049"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170199"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes253"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker361"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes147"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181945d2c"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.91"},{"key":"e_1_2_6_19_1","unstructured":"US Centers for Medicare and Medicaid Services.Medicare2019. URL:https:\/\/www.medicare.gov\/index."},{"key":"e_1_2_6_20_1","unstructured":"Independent Hospital Pricing Authority.National hospital cost data collection AR\u2010DRG cost weight tables V8.0x round 21 (financial year 2016\u201317). June2019. URL:https:\/\/www.ihpa.gov.au\/publications\/national\u2010hospital\u2010cost\u2010data\u2010collection\u2010ar\u2010drg\u2010cost\u2010weight\u2010tables\u2010v80x\u2010round\u201021."},{"key":"e_1_2_6_21_1","unstructured":"Australian Government Department of Health.The pharmaceutical benefits scheme. URL:http:\/\/www.pbs.gov.au\/pbs\/home."},{"key":"e_1_2_6_22_1","unstructured":"Australian Government Department of Health.Medicare benefits schedule. URL:http:\/\/www.mbsonline.gov.au\/internet\/mbsonline\/publishing.nsf\/Content\/Home."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-2120-7"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1149482"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2018.1386561"},{"key":"e_1_2_6_26_1","unstructured":"US Department of Veterans Affairs.Determining the cost of pharmaceuticals for a cost\u2010effectiveness analysis. URL:https:\/\/www.herc.research.va.gov\/include\/page.asp?id=pharmaceutical-costs."},{"key":"e_1_2_6_27_1","unstructured":"Congress of the United States Congressional Budget Office.Prices for brand\u2010name drugs under selected federal programs. June2005. URL:https:\/\/www.cbo.gov\/sites\/default\/files\/cbofiles\/ftpdocs\/64xx\/doc6481\/06\u201016\u2010prescriptdrug.pdf."},{"key":"e_1_2_6_28_1","unstructured":"US Department of Veterans Affairs.National Acquisition Center (CCST). URL:https:\/\/www.vendorportal.ecms.va.gov\/nac\/Pharma\/List."},{"key":"e_1_2_6_29_1","unstructured":"UpToDate. Colchicine. URL:https:\/\/www.uptodate.com\/contents\/colchicine\u2010drug\u2010information."},{"key":"e_1_2_6_30_1","unstructured":"Lexicomp.Lexicomp drug database. URL:https:\/\/online.lexi.com\/lco\/action\/login."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-019-0075-6"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.24357","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24357","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.24357","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:33:34Z","timestamp":1759422814000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.24357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/acr.24357"],"URL":"https:\/\/doi.org\/10.1002\/acr.24357","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"2019-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}